#USA #Brisbane #Corporate Governance #Pacira BioSciences #BLUE proxy

Pacira BioSciences Urges Stockholders to Vote the BLUE Proxy Card

In a proactive move ahead of its Annual Meeting scheduled for June 9, 2026, Pacira BioSciences, Inc. (Nasdaq: PCRX) has reminded its shareholders to vote for the candidates listed on the BLUE proxy card. The company emphasizes that selecting its three highly qualified nominees will safeguard the significant advancements made under its strategic 5x30 growth plan. This plan aims at securing sustainable growth and amplifying long-term shareholder value.

Valued Achievements and Growth

Pacira BioSciences, a frontrunner in advancing non-opioid pain management therapies, has seen considerable success in recent years. As noted by the management, 2025 marked a remarkable year with heightened total revenue, gross margins, and major achievements across its commercial offerings. The company reported a total revenue of $726.4 million and managed to post the highest annual gross margins in its history, reinforcing the efficacy of its growth strategy.

Going into 2026, Pacira's achievements through the first quarter reflect a year-over-year revenue increase, particularly with its flagship product, EXPAREL, reaching $143.3 million. Further, their products ZILRETTA and iovera° also posted sizeable revenue increases, indicating a robust market acceptance that continues to drive the company forward.

Expertise on the Board

The board of directors at Pacira has been crafted with an essential focus on expertise in biopharmaceutical development, commercialization, public policy, and operational excellence. According to recommendations from leading advisory firms such as International Shareholder Services (ISS), Glass Lewis, and Egan-Jones, the company’s governance structure is well positioned to enact the necessary oversight for both immediate execution and long-lasting growth initiatives.

The nominees — Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans — have distinguished records in public company board service and have successfully managed significant mergers and acquisitions. Their experience is directly pertinent to guiding Pacira's strategies and bolstering shareholder returns.

Countering DOMA's Challenge

Pacira is facing challenges from DOMA Perpetual Capital Management LLC, which is urging shareholders to consider alternative nominees. However, Pacira firmly believes that electing even one nominee from DOMA could jeopardize its current momentum and strategic coherence. The company cites that DOMA’s campaign lacks understanding of Pacira’s business framework and fails to present a viable plan for sustainable shareholder value.

Management strongly advises stockholders to disregard any white proxy cards that may arrive from DOMA, emphasizing the necessity of voting for Pacira’s preferred nominees to maintain the positive trajectory of the company.

Important Voting Instructions

All stockholders, regardless of their shareholding size, are encouraged to vote. The process is designed to be straightforward, allowing votes to be cast via proxy, internet, telephone, or mail. Should stockholders require assistance during the voting process, they can reach out to Pacira’s proxy solicitor, D.F. King & Co., Inc. at their toll-free numbers.

This is a significant moment for Pacira and its investors. Voting in favor of the nominated directors is crucial not only for corporate governance but also for the continual innovation and growth within the biopharmaceutical arena, which aims to transform patient lives through effective non-opioid pain management solutions.

For additional information on the voting process and insights regarding Pacira’s offerings, visit their official website.

About Pacira BioSciences

Pacira BioSciences specializes in innovative, non-opioid therapies aimed at revolutionizing pain management. The company's key products include EXPAREL, ZILRETTA, and iovera°, and it is actively working on expanding its pipeline for future growth in addressing musculoskeletal pain. With a dedicated approach toward patient-centered care, Pacira continues to lead the charge against addiction in pain management and foster robust partnerships in the healthcare sector. To find further details about their innovative solutions, please visit Pacira's website.